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Abstract
Recently, BRCA1 germline mutations were found in a high proportion (14–34%) of patients with triple-negative breast
cancer (TNBC). BRCA2 was either not analyzed or showed much lower mutation frequencies. Therefore, we screened a group
of TNBC patients (n=30) of white European descent for mutations in BRCA2 as well as in BRCA1. Cases were unselected for
age of disease-onset (median age at breast cancer diagnosis was 58 years, ranging from 37 to 74 years), family history of
cancer and BRCA1 and BRCA2 mutation status. Half of the patients (15/30) showed a family history of breast and/or ovarian
cancer. A high frequency of deleterious germline mutations was observed in BRCA2 (5/30; 16.7%), and only one case showed
a BRCA1 mutation (3.3%). Although the study group was small, these results point to BRCA2 mutations being important in
TNBC.
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Introduction
Recently, triple-negative breast cancer (TNBC) has been
classified as a breast cancer subgroup that is negative for estrogen
and progesterone receptors (ER/PR) and receptor 2 of human
epidermal growth factor (HER2). TNBC accounts for approxi-
mately 15% of all breast cancer cases and seems to be closely
related to basal-like breast cancer, which has an expression profile
similar to that of normal basal-myoepithelial breast tissue.
Approximately 80% of TNBC cases show a basal-like phenotype,
and the majority of basal-like breast cancers can be classified as
TNBC. Close to 75% of BRCA1-associated breast cancers is either
TNBC, basal-like breast cancer or both. TNBC patients have a
relatively poor outcome and cannot be treated with endocrine
therapy or therapies targeted to HER2 due to the lack of related
receptors [1].
Recent reports have focussed on BRCA1 germline mutations in
TNBC cases. In a Canadian TNBC cohort (n=54) with an age of
onset before 41 years and no familial breast cancer aggregation,
five cases with mutations of BRCA1 (9%) and only one case with a
mutation of BRCA2 (2%) were detected. The entire coding
sequence of BRCA1 and the large exons 10 and 11 of BRCA2 were
analyzed [2]. Of 73 TNBC cases from the United Kingdom (UK)
studied, 16 (22%) had BRCA1 mutations and none had BRCA2
mutations when fully screened in both genes. Forty-three of these
cases were from patients younger than 41 years of age at diagnosis
and with no familial aggregation of breast cancer. An additional
30 cases were unselected for family history of breast cancer
because they were younger than 31 years old at onset of the
disease [3]. In 77 TNBC cases from the United States that were
not selected for age or familial breast cancer occurrence, the
mutation frequencies were 15.6% for BRCA1 (n=12) and 3.9% for
BRCA2 (n=3). The entire coding sequence and the exon-intron
boundaries were screened in both genes [4]. Finally, a cohort of 64
Ashkenazi Jewish TNBC patients unselected for age of onset and
familial aggregation of breast cancer was screened for mutations in
BRCA1 and BRCA2. In all Ashkenazi Jewish breast cancer cases,
approximately 10% of patients carry one of three different founder
mutations in BRCA1 and BRCA2. In the investigated Ashkenazi
Jewish TNBC cohort (n=64), 19 BRCA1 (29.7%) and 6 BRCA2
(9.4%) mutations could be detected when screening for the three
founder mutations [5]. Given that the recent reports on TNBC
cases describe either no or low frequencies of BRCA2 mutations
[3,4], or refer to very special inbred populations with high founder
mutation frequencies [5], or report on incomplete BRCA2
mutation screening approaches [2], we aimed to investigate the
BRCA2 mutation frequency in a TNBC cohort of a Southern
German population unselected for age of onset and familial
aggregation of cancer. If there was a relevant mutation rate in such
cases, TNBC would meet the clinical criteria for mutation
screening in BRCA2 and should be added to the current guidelines.
Methods
Ethics statement
All selected patients underwent genetic counselling and gave
their written informed consent for genetic testing. The study
protocol was approved by the Ethics Committee of the State of
Salzburg (Austria).
Study population
In a monocentric approach executed in Munich, Germany,
newly diagnosed cases of individuals with TNBC diagnosed
between 2005 and 2010 were selected from the Pathology Unit.
Histological samples were classified as TNBC when the following
criteria were met: less than 1% of cells demonstrated nuclear
staining for estrogen and progesterone receptors, and immuno-
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| www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e38361histochemical staining for HER2 showing a 0, 1-fold, or a 2-fold
positive score and a FISH ratio (HER2 gene signals to
chromosome 17 signals) of less than 1.8 according to the relevant
ASCO and CAP guidelines [6]. No further selection criteria were
applied. For immunohistochemistry (IHC), we used IgG1 mouse
antibodies for estrogen (clone 6F11) and for progesterone receptors
(clone 16; both antibodies were purchased from DCS Innovative
Diagnostik-Systeme, Dr. Christian Sartori GmbH & Co. KG,
Hamburg, Germany). For HER2-IHC we used polyclonal rabbit
antibodies from clone A0485 (Hercep
TM-Test; Dako Deutschland
GmbH, Hamburg, Germany).
Genotyping
DNA extraction from whole blood samples (EDTA) was
performed according to standard protocols. To amplify exons
and exon-intron boundaries of BRCA1 and BRCA2, we used
primer pairs and polymerase chain reaction (PCR) protocols
published elsewhere [7]. PCR products were sequenced using
BigDyeH Terminator Cycle Sequencing Kits and 3730xl DNA
Analyzers with 96 capillary arrays according to the manufacturer’s
protocols (Applied Biosystems, Foster City, CA 94404 USA). To
exclude deletions and duplications of one or more exons, we
performed Multiplex Ligation-dependent Probe Amplification
(MLPA) of both genes according to the company’s technical
protocols (MRC-Holland, Amsterdam, the Netherlands). Muta-
tions and variants were classified according to the kConFab
classification scheme [8].
Clinical criteria for mutation screening in BRCA1 and
BRCA2
In Germany, patients with a 10% mutation probability are
eligible for mutation screening in BRCA1 and BRCA2. The
following clinical criteria were evaluated in approximately 1,000
unrelated cases in a German-wide study:
N Two women with breast cancer, with one of them #50 years,
or three women with breast cancer, independent of age.
N One woman with breast and one woman with ovarian cancer,
independent of age, or one woman with breast and ovarian
cancer, independent of age, or two women with ovarian
cancers, independent of age.
N One male breast cancer and one woman with breast or
ovarian cancer.
N One woman with breast cancer #35 years.
N One woman with bilateral breast cancer or two primary breast
cancers, with first tumour diagnosed before #50 years [9,10].
Results
Characteristics of investigated patients are presented in Table 1.
Six out of 30 TNBC patients (20%) carried a deleterious mutation
– one (1/30; 3.3%) in BRCA1 and five (5/30; 16.7%) in BRCA2.
We detected four known deleterious frame-shift mutations
(BRCA1: c.5266dupC (old nomenclature is ‘‘5382insC’’) which is
one of the most common deleterious BRCA1 mutations [11];
BRCA2: c.1029delA [12], p.S1882X [13], c.6444dupT accession
number 3790 in BIC database [http://research.nhgri.nih.gov])
and one unknown splice-site mutation (BRCA2: c.476-1G.A) with
a clear predictive deleterious effect. One missense mutation in
BRCA2 (p.W2626C) was classified as ‘‘predictive deleterious’’ in
prior literature [13].
In four cases, we detected c.4956G.Ai nBRCA1 leading to an
exchange of methionine for isoleucine at amino acid position
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c.5744C.T causes a point mutation of threonine to methionine
at amino acid position 1,915 of BRCA2 and was detected in four
cases (p.T1915M; 4/30; 13.3%). Within mutation carriers, two out
of six cases (33.3%) did not meet the German clinical criteria for
BRCA1 and BRCA2 testing. From all TNBC cases, 15 out of 30
(50%) showed an early age of onset or a familial aggregation which
are German clinical criteria for mutational screening of BRCA1
and BRCA2. The median age at diagnosis of the total study group
was 58 years (n=30), for mutations carriers 50 years (n=6), and
for the remaining patients (n=24) not showing deleterious
mutations 61 years.
Discussion
The aim of this study was to investigate the role of BRCA2
germline mutations in triple-negative breast cancer (TNBC). We
detected 6 deleterious BRCA1 and BRCA2 mutations in 30 TNBC
patients (20%). The total mutation frequency for both genes is
comparable with those described in recent studies [5,3,4,2]. In
contrast, we found a high frequency of BRCA2 germline mutations
in our TNBC study group: four cases with previously published
deleterious variants, and one splice-site mutation which was not
published before (16.7%). The low rate of BRCA2 mutations found
in a Canadian sample (1/54=2%) was probably the result of assay
design given that only exons 10 and 11 of BRCA2 were tested.
Additionally, only TNBC cases with an age of disease onset of less
than 41 years were selected for the study [2]. Our patient group
was not selected for age of disease onset; the average age was
57 years, with a median age of 58 years. This age difference
between the two study groups could also explain the inconsistent
frequencies of BRCA2 mutations. No BRCA2 mutations were
detected in 73 TNBC cases from the UK. BRCA1 and BRCA2
genes were fully screened, but patients were diagnosed with TNBC
before age 41 (n=43) and before age 30 (n=30). Cases were
selected for the UK study only if no familial aggregation was
reported [3]. In contrast, our TNBC group was not selected for
familial tumour aggregation or age of onset; these differences in
inclusion criteria may explain the different BRCA2 mutation
frequencies. Interestingly, a similar study of 77 TNBC cases from
the United States where cases were unselected for age of onset
(average was 51 years) revealed a much lower BRCA2 mutation
rate (3.9% vs. 16.7% in our study) [4].
Recently, data of a multi-national approach containing
approximately 7,000 BRCA1 and BRCA2 mutation carriers
(BRCA1: n=4,325; BRCA2: n=2,568) showed that the proportion
of TNBC increased with age at diagnosis in BRCA2 mutation
carriers, while it decreased in BRCA1 mutation carriers [14].
These findings are in accordance with our results since our patient
group tended to be older than those reporting lower BRCA2 and
higher BRCA1 mutations rates in TNBC [5,3,4,2].
In four cases, we detected c.4956G.Ai nBRCA1 (p.M1652I; 4/
30; 13.3%). Analysis with protein prediction software showed
some minor effect [15], so we decided to classify this variant as
reaching, at most, ‘‘low clinical significance’’ (LCS; table 1).
Variant c.5744C.T was detected in four cases (p.T1915M; 4/30;
13.3%). Methionine at amino acid position 1,915 of BRCA2
(rs4987117) was less frequent (OR 0.39, 95% CI 0.19 – 0.82,
p=0.013) in estrogen receptor-positive patients of a study cohort
of 117 sporadic breast cancer cases from Poland [16]. We
therefore classified this variant as ‘‘risk conferring polymorphism’’
(table 1). The two variants (c.4956G.Ai nBRCA1 and
c.5744C.Ti nBRCA2) could therefore be investigated in much
larger association studies to evaluate their impact in TNBC
tumorigenesis.
We identified deleterious BRCA2 mutations in two patients not
meeting the current German clinical criteria for BRCA1 and
BRCA2 mutation screening. In our cohort of TNBC patients
unselected for age at diagnosis and cancer family history, 15 cases
(15/30; 50%) did not meet those criteria. The mutation rate in this
subgroup was 13% (2/15). The main requirement for the German
clinical criteria for BRCA1 and BRCA2 mutation testing was
defined as being at least a 10% a priori probability to carry either a
BRCA1 or BRCA2 mutation [9,10]. If larger studies confirm our
findings, TNBC therefore may be included within clinical criteria
for BRCA1 and BRCA2 mutation screening, and additional cases
may be assessed not only if they present with early-onset of the
disease or have a familial aggregation of breast and/or ovarian
cancer. BRCA1 and BRCA2 mutation carriers are frequently
diagnosed with triple-negative breast cancer [14]. Nevertheless,
the German clinical selection criteria do not recommend BRCA1
and BRCA2 mutation screening in TNBC. In contrast, recent
guidelines published by the National Comprehensive Cancer
Network in the United States are less stringent. For instance,
TNBC diagnosed before age 60, and breast cancer cases with a
negative family history for cancer younger than 45 years should be
tested according to these guidelines. In comparison, the German
guidelines recommend testing single cases only if the diagnosis was
made before age 35 [9,10,17].
In summary, we found a 20% germline mutation rate (6/30
cases) in BRCA1 and BRCA2 genes in patients diagnosed with
TNBC from Southern Germany and unselected for age of disease
onset and familial aggregation of this malignant disease. In
contrast to recent reports, an unexpected and high mutation
frequency was seen in BRCA2 (5/30; 16.7%) suggesting that this
gene may play an important role in the development of TNBC
when mutated. Our data suggest that Southern German patients
diagnosed with TNBC may qualify for BRCA1 and BRCA2
mutation screening. Larger patient cohorts have to be investigated
to validate our findings.
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